Compound having ability to inhibit 11Beta-HSD1 enzyme or pharmaceutically acceptable salt thereof, method for producing same, and pharmaceutical composition containing same as active ingredient

摘要

The present invention relates to a novel compound or a pharmaceutically acceptable salt thereof inhibiting 11β-HSD1 enzyme activity, a preparation method of the same, and a pharmaceutical composition comprising the same as an active ingredient. Since the compound of the present invention selectively inhibits the activity of 11β-HSD1 (11β-Hydroxysteroid dehydrogenase type 1), the compound of the invention can be effectively used as a therapeutic agent for the treatment of diseases caused by the over-activation of 11β-HSD1 such as non-insulin dependent type II diabetes, insulin resistance, obesity, lipid disorder, metabolic syndrome, and other diseases or condition mediated by the excessive activity of glucocorticoid.

主权项

1. A compound or pharmaceutically acceptable salt thereof, wherein the compound is selected from the group consisting of the following compounds:
(3) E-4-[1-((2-fluoro-benzenesulfonylamino)methyl)cyclopropanecarboxamido]-adamantan-1-carboxylic acid amide; (22) E-4-[1-((2-fluoro-N-methyl-benzenesulfonylamino)methyl)cyclopropanecarboxamido]-adamantan-1-carboxylic acid amide; (71) E-4-[2-(2-fluoro-benzenesulfonylamino)-2-methylpropanamido]-adamantan-1-carboxylic acid amide; (84) E-4-[2-(2,6-difluoro-benzenesulfonylamino)-2-methylpropanamido]adamantan-1-carboxylic acid amide; (113) E-sodium[3-((5-carbamoyladamantan-2-yl)carbamoyl)phenyl]-2-fluoro-3-chloro-benzenesulfonylamide; and (119) E-4-[3-(3,5-dichloro-benzenesulfonylamino)-benzamido]-adamantan-1-carboxylic acid amide.